Share
USER HOTLINE: call us at +49 30 65499 145 | Not all products are available in the USA.

The Promise of Universal Plasma

HemoDefend-BGA is a development-stage filter designed to create “universal plasma” – plasma that does not need blood-typing and can be given off-the-shelf to anyone in need regardless of blood type – by removing anti-A and anti-B antibodies that make plasma blood-type specific.
*HemoDefend-BGA is a pre-clinical product under development that is not yet approved.

Many applications of life-saving plasma include trauma resuscitation, treatment of critically ill patients, and component purification, e.g.:

Clotting factors
Albumin
Intravenous immunoglobulin

In the U.S. alone, more than 10,000 units of fresh frozen plasma are administered daily, or 3.6 million units per year.

Replace standard plasma

 

With more than $16 million in funding from the U.S. Department of Defense, CytoSorbents has successfully developed and demonstrated a prototype HemoDefend-BGA adsorber that removes anti-A and anti-B antibodies from human plasma, with the goal of advancing our technology to human clinical trials and producing a one-size-fits-all low-titer “universal plasma” product that could replace standard plasma.

For partnership inquiries please contact us

Get in touch
CytoSorbents

Voices around the world

world map
Critical Care
Dr. Kai Singbartl
USA, Phoenix

The case represents the first successful application of CytoSorb in severe refractory neurotoxicity following treatment with chimeric-antigen-receptor T cells.

Critical Care
Dr. Maroua Eid
France, Angers

This case describes the successful use of CytoSorb with CRRT and extracorporeal life support in a combined way to overcome a critical phase of septic shock.

Critical Care
Assoc. Prof. Monir Sadat Hakemi
Iran, Tehran

It seems that applying the CytoSorb in combination with CRRT in ICU septic patients with AKI is correlated with a significant decrease in mortality.